| ISSN |
2150-5330 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Christopher K Murphy, Michelle M O'Donnell, James W Hegarty, Sarah Schulz, Colin Hill, R Paul Ross, Mary C Rea, Ronald Farquhar and Laurent Chesnel |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Laurent Chesnel, PhD, N/A, Research and Development, Adiso Therapeutics Inc., 530 Virginia Road, Suite 300, Concord, MA 01742, United States. lchesnel@adisotx.com |
| Key Words |
Gut; Single-strain live biotherapeutic product; ADS024; Clostridioides difficile; Clostridioides difficile challenge model; Microbiota |
| Core Tip |
Clostridioides difficile (C. difficile), a gram-positive pathogen associated with life-threatening gastrointestinal disease, colonizes millions of healthy people worldwide, causing disease in individuals with disrupted gut microbiomes. Here, we demonstrate in vivo efficacy of recently isolated Bacillus velezensis ADS024, without colonization, in protecting against C. difficile infection (CDI) challenge in mouse models. We also show that this novel strain has minimal effects on the gut microbiome in a human distal colon model and miniature swine. This study supports further investigation of ADS024 as a single-strain, live biotherapeutic product candidate for preventing recurrent CDI following successful standard-of-care antibiotic therapy. |
| Publish Date |
2023-08-24 14:27 |
| Citation |
Murphy CK, O'Donnell MM, Hegarty JW, Schulz S, Hill C, Ross RP, Rea MC, Farquhar R, Chesnel L. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo. World J Gastrointest Pathophysiol 2023; 14(4): 71-85 |
| URL |
https://www.wjgnet.com/2150-5330/full/v14/i4/71.htm |
| DOI |
https://dx.doi.org/10.4291/wjgp.v14.i4.71 |
